Botulinum Toxin for Masseter Slimming, Bruxism, and Hyperhidrosis

The aesthetic applications of botulinum toxin Type A are well understood by most practitioners — glabellar lines, forehead, crow's feet. But three of its most clinically impactful and commercially valuable applications fall outside the conventional upper face treatment plan: masseter reduction for jaw slimming and bruxism management, and eccrine gland denervation for hyperhidrosis.

These applications expand both your treatment menu and your patient base significantly. Masseter treatment attracts patients seeking facial contouring without surgery. Bruxism treatment brings in patients referred from dentists and patients in genuine chronic pain who have not found relief elsewhere. Hyperhidrosis treatment generates one of the highest patient loyalty rates in aesthetic medicine — patients who finally stop sweating through their clothing do not go anywhere else.

One important clinical and commercial point that applies across all three applications: they require substantially higher doses than conventional upper face treatment. A combined masseter and axillary hyperhidrosis appointment may use 160–220U of product in a single session. At these volumes, the product cost difference between European brands and MFDS-approved Korean botulinum toxins such as Botulax (letibotulinumtoxinA, Hugel) and Nabota (prabotulinumtoxinA, Daewoong) — both available through Celmade and both CE marked for UK and EU use — becomes very material to clinic economics. The clinical evidence supports 1:1 dosing equivalence for both products, and this guide uses that same dosing framework throughout.

All doses below are expressed in Botox-equivalent units. See our Unit Conversion guide for Botulax, Nabota, Bocouture, and Dysport equivalents. For the full clinical background on botulinum toxin mechanism and safety, see the Complete Guide to Botulinum Toxin Type A.

Part 1: Masseter Reduction — Jaw Slimming and Bruxism

Why Masseter Treatment Is One of the Most Rewarding Applications

Masseteric botulinum toxin treatment sits at a unique intersection of aesthetics and function. For cosmetic patients, it reshapes the lower face from a square, angular contour toward an oval or tapered profile — an effect that takes 2–4 months to fully develop as the muscle atrophies, but that persists and improves with successive treatments. For bruxism patients, it reduces the contractile force of the masseter during clenching and grinding, providing measurable relief for TMJ dysfunction, headaches, and dental wear.

In both Korean and European aesthetic practice, masseteric toxin treatment has become a core treatment in the lower face toolkit. The Korean aesthetic market — where V-line jaw contouring is one of the most requested non-surgical procedures — has generated a substantial real-world evidence base for this treatment across tens of thousands of patients. Products like Botulax and Nabota, both manufactured under MFDS oversight in South Korea, are used for masseteric treatment in Korean clinics at the same 1:1 Botox-equivalent doses used in European practice and with comparable results. UK practitioners can apply this same clinical framework with confidence.

Anatomy of the Masseter

The masseter is a powerful quadrilateral muscle of mastication with two heads:

•       Superficial head: Originates from the anterior two-thirds of the zygomatic arch and inserts on the angle and lower lateral surface of the mandibular ramus. This is the largest and most clinically accessible head and the primary target for jaw slimming injection.

•       Deep head: Originates from the posterior third of the zygomatic arch and inserts on the upper ramus and coronoid process. It lies deep to the superficial head and is not a primary target for cosmetic injection — attempting to treat it increases the risk of parotid diffusion and facial nerve involvement.

The masseter is innervated by the masseteric nerve (a branch of V3 — the mandibular division of the trigeminal nerve), not the facial nerve. Correctly placed injections therefore carry no risk of facial weakness. The risk of facial nerve involvement arises only from injections placed too anteriorly or too superiorly, where the marginal mandibular and buccal branches run near the parotid gland.

Borders and Safe Injection Zone

Defining the safe injection zone before treatment is mandatory — palpate all four borders of the masseter with the patient clenching:

•       Superior border: The zygomatic arch. Stay below this at all times — injection above risks the temporal branch of the facial nerve and the temporal fat pad.

•       Anterior border: The anterior edge of the masseter as felt during clenching. Stay at least 1 cm posterior to this border — injecting anteriorly risks the parotid duct, the buccal branch of the facial nerve, and the facial vessels.

•       Inferior border: The inferior mandibular border (angle of the mandible). Injection below this border risks the marginal mandibular nerve, causing an asymmetric lower lip that may persist for the full duration of toxin effect.

•       Posterior border: The posterior masseter edge and parotid region. Do not inject posterior to the muscle belly.

Dosing

The following doses apply directly to Botulax and Nabota at 1:1 Botox-unit equivalence — no conversion required. For Dysport, multiply by 2.5.

Product Note: Why Korean Toxins Work Particularly Well at Masseter Doses

At 25–60U per side for a single muscle group, the economics of product choice become directly visible in your margin sheet. Botulax 100U and Nabota 100U — both MFDS-approved and CE-marked products with confirmed 1:1 clinical equivalence to Botox — cost a fraction of Allergan's product at the same unit count. A busy clinic performing 5 masseter treatments per week can generate meaningful additional annual margin simply by switching to a Korean alternative at the same dosing. The clinical result is equivalent; the patient experience is unchanged; only the cost base shifts. For 200U and 50U vial formats suited to high-volume masseter practices, see Celmade's botulinum toxin range.

Injection Technique

Number of injection points: 3–5 points per side, distributed in a grid pattern across the lower two-thirds of the muscle belly. More points at lower individual doses produce more even distribution — better for large muscles and for cosmetic treatments where even atrophy is the goal.

Needle depth — intramuscular: Insert the needle perpendicular to the skin and advance until you feel the resistance change of entering the muscle. The masseter is a thick muscle — in a patient with significant hypertrophy, the muscle belly may be 1.5–2 cm deep. Subcutaneous injection delivers product that diffuses poorly into the muscle.

Confirming muscle position: Ask the patient to clench as you advance the needle. The muscle will contract around the needle, confirming correct intramuscular placement. Release the clench before injecting — injecting into a contracting muscle increases product backflow and bruising risk.

Patient position: Seated upright. Mark the injection grid before the patient reclines — the masseter position shifts slightly with head position and gravity.

Setting Realistic Expectations for Jaw Slimming

Bruxism: Additional Clinical Considerations

For patients presenting primarily with bruxism, the consultation differs from a cosmetic jaw-slimming consultation in several important ways:

•       Symptom assessment: Document the specific symptoms — tooth grinding (sleep or waking), jaw clenching, morning jaw pain, headaches (temporal or occipital), dental wear or cracking. These are the endpoints against which treatment success will be measured at the 2-week review.

•       Dentist communication: Patients with bruxism often have a dentist managing the dental consequences. Communicating with the dentist — and where possible, treating from a formal referral — strengthens the clinical rationale and supports the case if any medico-legal issues arise.

•       Temporalis involvement: In patients with significant temporal headaches related to bruxism, the temporalis muscle (the fan-shaped muscle at the temple) can be co-treated. Dose: 15–25U per side at 3–4 injection points across the muscle belly. With Botulax or Nabota at 1:1 equivalence, this adds no conversion complexity to the session.

•       Onset for pain relief: Bruxism-related pain relief typically begins within 1–2 weeks as clenching force reduces — much earlier than the cosmetic slimming effect. Set this expectation clearly at consultation so patients understand the two timelines.

For the clinical evidence base for masseteric botulinum toxin in bruxism and TMJ dysfunction, see Shim et al. (2014) in the Journal of Oral & Maxillofacial Surgery and the systematic review by Awan et al. (2019) in Oral Surgery, Oral Medicine, Oral Pathology, which evaluated botulinum toxin for temporomandibular disorders across multiple RCTs.

Complications and How to Avoid Them

Part 2: Hyperhidrosis — Axillary, Palmar, and Plantar

The Clinical Case for Hyperhidrosis Treatment

Primary hyperhidrosis — excessive sweating beyond what is physiologically necessary for thermoregulation — affects an estimated 1–3% of the population and has a profound impact on quality of life. Patients with severe axillary hyperhidrosis routinely report avoiding social situations, wearing only dark-coloured clothing, and experiencing significant psychological distress. Many have tried prescription antiperspirants without adequate relief.

Botulinum toxin for hyperhidrosis has one of the strongest evidence bases of any aesthetic application — it is licensed for axillary hyperhidrosis in most European countries and the UK, with Level 1 evidence from multiple RCTs. Duration of effect for hyperhidrosis (6–12 months) is substantially longer than for cosmetic facial applications, which makes it highly cost-effective for patients and commercially excellent for clinics in terms of treatment value and patient retention.

Hyperhidrosis treatment is also one of the applications where the high dose volumes involved make Korean product selection most clinically relevant. Treating both axillae with 100U total, or both palms with 200–300U, from a Nabota 200U vial (available through Celmade) covers a full bilateral axillary treatment from a single vial — a logistical and economic efficiency that significantly changes the per-treatment cost calculation compared to using 100U European brand vials.

Mechanism: Why Toxin Works for Sweating

Eccrine sweat glands — the primary glands responsible for hyperhidrosis — are innervated by cholinergic sympathetic fibres. These fibres release acetylcholine to stimulate sweat production, using the same neurotransmitter pathway that botulinum toxin blocks at the neuromuscular junction. Intradermal injection of botulinum toxin around eccrine glands blocks acetylcholine release at the neuro-glandular junction, producing localised cessation of sweating. The mechanism is identical to neuromuscular blockade — only the target tissue (gland vs muscle) differs.

Importantly, this mechanism is product-independent — Botulax and Nabota block acetylcholine at eccrine glands with the same efficacy as Botox at equivalent units. The foundational Naumann et al. (2001) RCT in Archives of Dermatology established botulinum toxin Type A as an effective and safe treatment for primary axillary hyperhidrosis, with the conclusions applicable to any licensed Type A product at equivalent dosing.

Patient Assessment and the Minor's Iodine-Starch Test

Before treating hyperhidrosis, map the exact area of excessive sweating using the Minor's iodine-starch test. This simple procedure visualises the sweating zone precisely, ensuring injection points cover the active area and that product is not wasted in non-sweating regions:

1.     Clean and dry the treatment area completely.

2.     Apply a thin layer of Lugol's iodine solution to the skin and allow to dry for 1–2 minutes.

3.     Dust the area liberally with cornstarch or rice starch powder.

4.     As sweating occurs (encourage by warming the room or asking the patient to exercise lightly beforehand), the iodine-starch combination turns dark blue-black precisely where sweat is present.

5.     Mark the boundary of the active sweating zone with a skin marker. This is your treatment area.

Axillary Hyperhidrosis: Dosing and Technique

The following doses apply directly to Botulax and Nabota at 1:1 equivalence. At 50U per axilla, a single Nabota 100U vial covers one complete bilateral axillary treatment — or a Botulax 200U vial covers two complete bilateral sessions, making stock planning straightforward.

Injection grid: Place injection points in a grid pattern 1–1.5 cm apart across the entire marked sweating zone. Each injection delivers approximately 2U per point (at 50U over ~25 points per axilla). Use a fine-gauge needle (30G) and inject intradermally — a small bleb should form at each point, confirming correct depth.

Pain management: Axillary injections are well-tolerated by most patients without anaesthesia. For sensitive patients, EMLA cream applied 45–60 minutes before treatment, or ice applied immediately before each injection point, provides adequate comfort.

Onset and duration: Patients typically notice significant reduction in sweating within 5–7 days. Full effect is reached at 2 weeks. Duration ranges from 6–12 months — considerably longer than facial applications. Use the Hyperhidrosis Disease Severity Scale (HDSS) at the 2-week review to objectively document treatment response.

Palmar Hyperhidrosis: Dosing and Technique

Palmar hyperhidrosis responds well to botulinum toxin but requires significantly higher doses than axillary treatment, a comprehensive injection grid, and adequate anaesthesia — the palmar surface is densely innervated and highly pain-sensitive.

At 100–150U per hand (200–300U total for both hands), palmar treatment represents one of the highest single-session doses in aesthetic practice. At this volume, using Botulax 200U or Nabota 200U vials rather than multiple 100U vials of European alternatives significantly reduces both product cost and the number of vials needed per appointment. The 200U vial format, available through Celmade, is purpose-suited for this application.

•       Anaesthesia is essential: Palmar injections are significantly more painful than axillary treatment. Options include median and ulnar nerve blocks (most comfortable), wrist nerve blocks, or topical EMLA under occlusion for 90 minutes (partial effect only). A formal nerve block at the wrist is the gold standard — never attempt palmar treatment with topical anaesthesia alone.

•       Injection grid: Map the palmar sweating zone with the Minor's test first. Inject in a 1–1.5 cm grid across the entire palm including thenar and hypothenar eminences. Avoid the web spaces and palmar creases. Use the finest gauge needle available — 31 or 32G.

•       Intrinsic muscle weakness risk: Temporary weakness of pinch grip and fine motor tasks can occur post-treatment for 2–4 weeks. Warn all palmar patients of this risk before treatment — particularly those whose work involves fine manual tasks, musical instruments, or surgical procedures.

Plantar Hyperhidrosis: Dosing and Technique

Plantar (sole of foot) hyperhidrosis requires general or regional anaesthesia in most patients due to the extreme pain of plantar injection and the thickness of plantar skin. It should only be performed by practitioners with sufficient experience in regional nerve blocks, or in collaboration with an anaesthetist.

Patient Selection: Who Is a Good Candidate?

Adding These Treatments to Your Clinic: The Product and Margin Case

Masseter and hyperhidrosis treatments represent a significant commercial opportunity — and one where product choice has an outsized effect on margin.

Key Takeaways

•       Masseter treatment is cosmetic AND functional: jaw slimming and bruxism relief are both achievable from the same injection session — adjust dosing emphasis based on the patient's primary goal.

•       Define the safe injection zone before every masseter treatment: palpate all four borders — zygomatic arch, anterior masseter, mandibular angle, and parotid boundary — before every injection.

•       Cosmetic masseter results take 3–4 months: set this expectation at consultation, not at the 2-week review when the patient asks why nothing has changed yet.

•       Hyperhidrosis uses the same mechanism as cosmetic toxin: cholinergic blockade — at eccrine glands instead of the neuromuscular junction. The technique differs (intradermal grid, higher dose) but the product is identical.

•       Map axillary sweating with the Minor's iodine-starch test: 5 minutes of preparation prevents wasted product and missed zones.

•       Never treat palmar hyperhidrosis without adequate anaesthesia: a nerve block at the wrist is the clinical standard — topical anaesthesia alone is insufficient.

•       High-dose applications are where Korean product selection makes the biggest difference: at 100–300U per treatment session, the cost saving from using Botulax or Nabota at 1:1 Botox-equivalent dosing compounds quickly across a busy clinic schedule. Both are CE marked, MFDS approved, and clinically equivalent — and both are available through Celmade in the 200U vial format suited to these applications.

For our full botulinum toxin clinical series, see the Complete Guide to Botulinum Toxin Type A, Brand Comparison guide, Unit Conversion reference, and our Upper Face Dosing guide. Browse the full botulinum toxin range on Celmade, including Botulax and Nabota in 50U, 100U, and 200U vials.

Frequently Asked Questions

How many sessions does masseter slimming typically take?

Most patients see meaningful jaw slimming after 2–3 sessions spaced 4–6 months apart. The first session initiates muscle atrophy; the second builds on it; by the third, most patients have reached their desired contour. Heavily hypertrophied masseters in male patients may need 3–4 sessions. Korean aesthetic clinics — where V-line jaw contouring is a core treatment — routinely follow this same multi-session protocol with Botulax and Nabota at identical doses to those used in European practice.

Will masseter treatment affect chewing or eating?

At correctly dosed cosmetic levels, the effect on chewing is minimal — the masseter is a powerful muscle and partial reduction is well-compensated by the remaining masticatory muscles. Some patients notice mild jaw fatigue with very tough foods in the first few weeks post-treatment. At higher bruxism doses, a small proportion of patients describe a temporary sensation of reduced chewing force, which resolves as the toxin wears off. Advise all patients to avoid excessively tough or chewy foods for 2–4 weeks post-treatment as a precaution.

How long does hyperhidrosis treatment last?

Axillary hyperhidrosis treatment typically lasts 6–12 months — significantly longer than cosmetic facial applications. Palmar and plantar treatments generally last 4–6 months. The extended duration is consistent across botulinum toxin Type A products including Botulax and Nabota at equivalent doses. Advise patients to return before sweating fully resumes — treating before complete return of sweating maintains quality-of-life improvement and may extend the effective period over time.

Is Botulax safe and effective for hyperhidrosis at the same dose as Botox?

Yes. Botulax (letibotulinumtoxinA, Hugel) and Nabota (prabotulinumtoxinA, Daewoong) are both used at 1:1 Botox-equivalent dosing across all applications, including hyperhidrosis. The mechanism — cholinergic blockade at eccrine glands — is product-independent. Both are CE marked for UK and EU use and MFDS approved. Real-world evidence from Korean aesthetic practice, where these products have been used at scale for hyperhidrosis treatment, supports equivalent clinical outcomes. For more detail on the evidence base for Korean botulinum toxin products, see our Brand Comparison guide.

Can I treat masseter and hyperhidrosis in the same appointment?

Yes — there is no clinical reason they cannot be combined. A typical combined session (60U masseter + 100U axillary) uses 160U total, well within normal clinical volumes at a single appointment. From a product planning perspective, a Botulax or Nabota 200U vial covers the entire combined session from a single vial, making the appointment logistically clean and cost-efficient. Document the total dose administered and the site-specific breakdown in the patient record.